Confirmatory interleukin-1 receptor antagonist trial in severe sepsisSteven M. Opal, Michael G. Seneff, H. C. E. Donovan et al.|Critical Care Medicine|1997Cited by 863
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic ShockSteven M. Opal, Jon H. Lemke, Patrick J. Scannon et al.|The Journal of Infectious Diseases|1999Cited by 611
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trialCharles J. Fisher, Michael A. Catalano, Gus J. Slotman et al.|Critical Care Medicine|1994Cited by 490
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*Steven M. Opal, John P. Pribble, Pierre‐François Laterre et al.|Critical Care Medicine|2004Cited by 145
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial*Daniel P. Schuster, John P. Pribble, Michael H. Metzler et al.|Critical Care Medicine|2003Cited by 82